Traders Sell Shares of Pfizer (PFE) on Strength (PFE)
Investors sold shares of Pfizer Inc. (NYSE:PFE) on strength during trading hours on Monday. $113.24 million flowed into the stock on the tick-up and $213.10 million flowed out of the stock on the tick-down, for a money net flow of $99.86 million out of the stock. Of all equities tracked, Pfizer had the 4th highest net out-flow for the day. Pfizer traded up $0.67 for the day and closed at $44.18
Several equities research analysts recently commented on the stock. ValuEngine upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Tuesday, October 9th. Morningstar set a $46.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, October 9th. Independent Research set a $48.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research report on Thursday, October 4th. Barclays set a $40.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research report on Friday, October 19th. Finally, Cantor Fitzgerald set a $45.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Thursday, October 4th. Two research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eight have given a buy rating to the company’s stock. Pfizer presently has an average rating of “Hold” and an average price target of $42.67.
The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.15 and a current ratio of 1.43. The firm has a market capitalization of $259.01 billion, a PE ratio of 16.67, a P/E/G ratio of 2.19 and a beta of 0.88.
The company also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Friday, November 9th will be issued a dividend of $0.34 per share. The ex-dividend date of this dividend is Thursday, November 8th. This represents a $1.36 annualized dividend and a yield of 3.08%. Pfizer’s payout ratio is 51.32%.
In related news, major shareholder Pfizer Inc acquired 55,556 shares of the stock in a transaction dated Monday, October 15th. The stock was bought at an average price of $18.00 per share, for a total transaction of $1,000,008.00. Following the purchase, the insider now directly owns 21,976,484 shares of the company’s stock, valued at approximately $395,576,712. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.06% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. Fort L.P. bought a new stake in Pfizer during the 2nd quarter valued at $121,000. W.G. Shaheen & Associates DBA Whitney & Co bought a new stake in Pfizer during the 1st quarter valued at $132,000. Braun Bostich & Associates Inc. bought a new stake in Pfizer during the 1st quarter valued at $139,000. Smart Portfolios LLC increased its stake in Pfizer by 43.9% during the 2nd quarter. Smart Portfolios LLC now owns 3,935 shares of the biopharmaceutical company’s stock valued at $143,000 after purchasing an additional 1,200 shares in the last quarter. Finally, Selective Wealth Management bought a new stake in Pfizer during the 3rd quarter valued at $155,000. Institutional investors own 68.64% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Traders Sell Shares of Pfizer (PFE) on Strength (PFE)” was reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.dailypolitical.com/2018/11/19/traders-sell-shares-of-pfizer-pfe-on-strength-pfe.html.
About Pfizer (NYSE:PFE)
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
See Also: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.